Provided by Tiger Trade Technology Pte. Ltd.

TG Therapeutics

31.92
-0.0600-0.19%
Volume:722.88K
Turnover:23.16M
Market Cap:5.10B
PE:11.50
High:32.32
Open:31.76
Low:31.31
Close:31.98
52wk High:46.48
52wk Low:25.28
Shares:159.69M
Float Shares:148.00M
Volume Ratio:0.49
T/O Rate:0.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.78
EPS(LYR):2.77
ROE:102.75%
ROA:9.39%
PB:7.87
PE(LYR):11.52

Loading ...

TG Therapeutics Shares Hit Highest Since November, Last up 12.9% After Prelim 2025 Sales Top Estimate

THOMSON REUTERS
·
Jan 14

Unusually active option classes on open January 14th

TIPRANKS
·
Jan 14

Stock Track | TG Therapeutics Soars 17.83% Intraday on Strong Revenue Outlook and Briumvi Sales

Stock Track
·
Jan 14

BUZZ-U.S. STOCKS ON THE MOVE-Prologis, Huntington Ingalls, Citigroup

Reuters
·
Jan 14

TG Therapeutics Shares Jump 9.8% Premarket After Preliminary 2025 Net Sales Above Forecast

THOMSON REUTERS
·
Jan 14

Stock Track | TG Therapeutics Soars 7.18% in Pre-Market on Raised Revenue Guidance and Strong Briumvi Sales

Stock Track
·
Jan 14

Stocks to Watch Wednesday: Netflix, Bank of America, Citi -- WSJ

Dow Jones
·
Jan 14

Bank of America, Citigroup And 3 Stocks To Watch Heading Into Wednesday

Benzinga
·
Jan 14

Stock Track | TG Therapeutics Soars 7.61% on Strong 2025 Results and Optimistic 2026 Revenue Guidance

Stock Track
·
Jan 14

BUZZ-TG Therapeutics jumps after preliminary 2025 sales exceed forecast

Reuters
·
Jan 14

BRIEF-Tg Therapeutics Provides Preliminary Fourth Quarter And Full Year 2025 Results

Reuters
·
Jan 14

TG Therapeutics Stock Climbs After The Bell: Here's Why

Benzinga
·
Jan 14

TG Therapeutics Announces Strong 2025 BRIUMVI Revenue Outlook

TIPRANKS
·
Jan 14

TG Therapeutics Issues 2026 Revenue Outlook; Shares Rise After Hours

MT Newswires Live
·
Jan 14

TG Therapeutics reports preliminary Q4 revenue $182M, consensus $182.38M

TIPRANKS
·
Jan 14

TG Therapeutics sees FY26 revenue $875M-$900M, consensus $895.63M

TIPRANKS
·
Jan 14

TG Therapeutics Targets Up to $900 Million Global Revenue in 2026

Reuters
·
Jan 14

TG Therapeutics Inc - 2026 Global Revenue Target $875-900 Mln, Briumvi U.S. $825-850 Mln

THOMSON REUTERS
·
Jan 14

TG Therapeutics Inc - Phase 1 Azer-Cel Data in Progressive MS Expected Second Half 2026

THOMSON REUTERS
·
Jan 14

TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones

THOMSON REUTERS
·
Jan 14